Vaxcyte Initiates Phase 1 Study for VAX-A1 Vaccine Candidate
Vaxcyte (NASDAQ:PCVX) has initiated the first participant dosing in its Phase 1 clinical trial evaluating the investigational prophylactic vaccine candidate, VAX-A1. The study aims to assess safety and tolerability of the vaccine for preventing Group A Streptococcus disease in healthy adults aged 18-40.
Tickers: $PCVX
Topics: Group A Streptococcus Phase 1 trial vaccine development